FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Research/Semaglutide and Closed Loop Systems: A New Approach for Type 1 Diabetes Management
Back to Research Library

Semaglutide and Closed Loop Systems: A New Approach for Type 1 Diabetes Management

November 20, 2026
Share
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article is an AI-assisted summary of a recently published news item or clinical trial listing. It is intended to provide a quick, accessible overview for the peptide research community. For full accuracy, always refer to the original source linked below.

Semaglutide and Closed Loop Systems: A New Approach for Type 1 Diabetes Management

A new clinical trial aims to simplify carbohydrate counting for patients with type 1 diabetes (T1D) by combining a closed-loop insulin system with weekly subcutaneous semaglutide injections. The study, titled "Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide," is currently recruiting participants and is being conducted at the Research Institute of the McGill University Health Centre.

Background

Type 1 diabetes (T1D) management can be challenging, requiring constant monitoring of blood glucose levels and precise insulin dosing. One common method for managing T1D is carbohydrate counting, which involves estimating the amount of carbohydrates in meals to determine appropriate insulin doses. However, this process can be time-consuming and complex, leading to potential errors that may affect glycemic control.

The advent of closed-loop insulin systems, often referred to as "artificial pancreas" (AP) technology, has shown promise in improving glucose management for T1D patients. These systems integrate an insulin pump with a continuous glucose monitor (CGM), using advanced algorithms to adjust insulin delivery automatically based on real-time blood sugar levels.

Semaglutide is another tool used primarily in the treatment of type 2 diabetes and obesity. It works by mimicking glucagon-like peptide-1 (GLP-1) hormones, which help regulate blood glucose levels through various mechanisms including delayed gastric emptying and increased insulin secretion. Recently, researchers have been exploring semaglutide's potential benefits for T1D patients as well.

Key Details

The current study, funded by the Research Institute of the McGill University Health Centre, seeks to evaluate how combining weekly subcutaneous semaglutide injections with a closed-loop system can improve glycemic control and reduce the burden of carbohydrate counting in individuals with type 1 diabetes. Participants will be randomly assigned to one of two groups: those receiving semaglutide or a placebo, each paired with four different meal strategies designed to test various dietary scenarios.

The primary objective is to determine if this combined approach can lead to better glucose regulation without the need for meticulous carbohydrate counting. Secondary goals include assessing overall quality of life and adherence to treatment protocols among participants.

Key Takeaways

  • Simplifying Diabetes Management: The study aims to reduce the complexity involved in managing type 1 diabetes by integrating semaglutide with a closed-loop insulin system.
  • Improved Glycemic Control: Researchers hope that this combination therapy will enhance blood sugar regulation, potentially leading to fewer fluctuations and better long-term outcomes for T1D patients.
  • Reduced Burden on Patients: By alleviating the need for constant carbohydrate counting, the trial seeks to make daily diabetes management easier and more manageable for individuals living with type 1 diabetes.
  • Potential New Treatment Option: If successful, this approach could offer a novel therapeutic strategy that leverages both peptide therapy (semaglutide) and advanced technology (closed-loop system).

What This Means

For the peptide research community, this study represents an important step forward in understanding how semaglutide can be effectively used beyond its current indications. The integration of semaglutide with cutting-edge closed-loop systems could open up new avenues for improving diabetes care and patient outcomes. As more clinical trials like these continue to explore innovative combinations of peptide therapies and technological advancements, the landscape of diabetes management is likely to see significant changes in the coming years.

---

Source: ClinicalTrials.gov — Published 2026-11-19

This article is for informational purposes only and does not constitute medical advice.

Editor's Note

This analysis was generated using AI tools and reviewed by the Peptide Contacts editorial team. While we strive for accuracy, AI-generated content may contain errors or omissions. We encourage readers to review the original source for complete details, methodology, and data.

Peptide Contacts provides curated research summaries for informational purposes only. This content does not constitute medical advice. Always consult a qualified healthcare provider before making any health decisions.

Comments

Sign in to join the discussion

This article was generated using AI and may contain inaccuracies. It is provided for informational purposes only and does not constitute medical advice. Always verify information with the original source and consult a qualified healthcare provider before making any health decisions.